Earnings Performance - Adjusted loss per share of 25 cents, beating the Zacks Consensus Estimate of 27 cents by 7.4% [1] - GAAP loss per share narrowed to 46 cents from 1.03intheprior−yearquarter[1]RevenueGrowth−Totalrevenuesof180.9 million, beating the Zacks Consensus Estimate by 1.8% and growing 32.9% year-over-year [2] Segmental Performance Geonomics - Sales of 116.4million,up20.357.4 million, up 14.2% year-over-year, with adjusted gross margin contracting 260 bps to 49.3% [3] Data and Services - Sales of 64.5million,up64.450.5 million, up 112.6% year-over-year, with adjusted gross margin expanding 1780 bps to 78.3% [3] Margins and Expenses - Adjusted gross profit of 107.9million,up45.8139.3 million, up 17.2% year-over-year [4] - Total loss from operations of 53.6million,expanding19.7467.2 million at the end of Q3 2024, down from 490.9millionattheendofQ22024[5]−Cumulativenetcashusedinoperatingactivitiesof149.8 million, down from 174.1millionayearago[5]2024Guidance−Full−year2024revenueguidanceofapproximately700 million, representing a 32% year-over-year growth, slightly above the Zacks Consensus Estimate of 696.7million[6]StrategicDevelopments−Multi−yearcollaborationwithBioNTechtoleverageTempus′TCRdatasetforBioNTech′snext−generationoncologypipeline[9]−Three−yearextensionofthestrategicagreementwithMerckEMD[9]−AgreementtoacquireAmbryGeneticsfor375 million in cash and 225millioninshares,with100 million subject to a lock-up agreement [10] Stock Performance - Shares lost 6.1% during after-market trading following Q3 results but gained 23% in the past six months, outperforming the industry's 8.1% rise and the S&P 500's 10.1% increase [8] Industry Comparison - AngioDynamics (ANGO) shares lost 19.2% year-to-date, underperforming the industry's 6.1% growth [12] - Quest Diagnostics (DGX) shares gained 42% year-to-date, outperforming the industry's 14.9% growth [12] - RadNet (RDNT) shares surged 93.7% year-to-date, significantly outperforming the industry's 14.8% growth [13]
